Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma

25 Jan 2025

Abstract excerpt

offers the potential to improve patient outcomes. Since PTEN deficiency is common in cancer and is the main mechanism for capivasertib function, combination therapy may provide an alternative solution for the challenges of CAR T cell therapy.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Lymphoma Diagnosis and Treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40008088
DOI: 10.1016/j.omtm.2025.101421

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphomaPMID 40008088Read ↗

"The emerging role of capivasertib in breast cancer".Semantic proximity Read ↗

Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphomaSemantic proximity Read ↗

Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.Semantic proximity Read ↗

Pharmacovigilance Signal Detection and Mutually Exclusive Driver Mutations of the PI3K/AKT Pathway in Breast Cancer Treated With Capivasertib.Semantic proximity Read ↗

Dual Targeting of Akt and MAPK Pathways With Capivasertib and B-Raf Inhibitors Synergistically Suppresses Tumor Growth in B-Raf-Mutated Melanoma Models.Semantic proximity Read ↗

Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)Semantic proximity Read ↗

A phase II Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN -Inactivating MutationsSemantic proximity Read ↗

From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.